Dorsey & Whitney Trust CO LLC Acquires 4,628 Shares of Moderna, Inc. (NASDAQ:MRNA)

Dorsey & Whitney Trust CO LLC raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 187.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,091 shares of the company’s stock after purchasing an additional 4,628 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Moderna were worth $756,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Moderna in the fourth quarter valued at about $27,000. Arlington Trust Co LLC increased its holdings in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the period. Westside Investment Management Inc. acquired a new stake in shares of Moderna in the first quarter valued at approximately $32,000. Rise Advisors LLC boosted its stake in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the period. Finally, UMB Bank n.a. grew its position in Moderna by 121.8% during the first quarter. UMB Bank n.a. now owns 366 shares of the company’s stock worth $39,000 after buying an additional 201 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. UBS Group raised their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, June 28th. Evercore ISI reaffirmed an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Finally, Oppenheimer boosted their target price on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 12th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $134.02.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 255 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the transaction, the president now directly owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, President Stephen Hoge sold 255 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the transaction, the president now owns 1,486,508 shares in the company, valued at $179,808,007.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $122.84, for a total transaction of $1,842,600.00. Following the completion of the sale, the director now directly owns 2,254,015 shares in the company, valued at approximately $276,883,202.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 396,239 shares of company stock valued at $55,286,137. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Down 0.1 %

Shares of MRNA traded down $0.18 during trading hours on Friday, reaching $121.14. The stock had a trading volume of 2,205,687 shares, compared to its average volume of 4,079,017. The company has a market capitalization of $46.43 billion, a price-to-earnings ratio of -7.73 and a beta of 1.66. The firm has a 50-day simple moving average of $135.37 and a 200 day simple moving average of $114.52. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.19 EPS. Equities research analysts predict that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.